Role of 68Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Rakesh Kumar & Punit Sharma & Pramod Garg & Sellam Karunanithi & Niraj Naswa & Raju Sharma & Sanjay Thulkar & Sneh Lata & Arun Malhotra
- چاپ و سال / کشور: 2011
Description
Objective The objective of the present study was to evaluate the role of 68Ga-DOTA(0)-Phe(1)-Tyr(3)-octreotide (68Ga-DOTATOC) positron emission tomography computed tomography (PET-CT) for detection and staging of pancreatic neuroendocrine tumours (NETs). Methods Twenty patients with clinically suspected and/or histopathologically proven pancreatic NET underwent 68Ga-DOTATOC PET-CT imaging for staging and /or localisation of primary lesion. They also underwent contrast enhanced CT (CECT) and 8 patients underwent 18F-FDG PET-CT. SUVmax of primary and metastatic lesions were measured. Results were verified with histopathology for primary tumour and with clinical follow up/MRI and /or biopsy for metastatic disease. Results of 68Ga-DOTATOC PET-CT were compared to CECT and 18F-FDG PET-CT. Results 68Ga-DOTATOC PET-CT correctly localised primary in all 20, CECT in 15 and 18F-FDG PET-CT in 2 patients. 68Ga-DOTATOC PET-CT demonstrated metastases in 13 patients, CECT in 7 and 18F-FDG PET-CT in 2. 68Ga- DOTATOC PET-CT emerged as the best investigation with 100% sensitivity and PPV for detecting primary tumour and metastatic disease. The detection rate of CECT was lower than 68Ga-DOTATOC PET-CT, both for primary tumour (20vs.15) or metastatic disease (13vs.7). 18F-FDG PET-CT performed poorly for primary and metastasis. Conclusion Ga-DOTATOC PET-CT is a very useful imaging investigation for diagnosing and staging pancreatic NET.
Eur Radiol DOI 10.1007/s00330-011-2199-y Received: 28 January 2011 / Revised: 29 April 2011 / Accepted: 6 May 2011
